<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36233149</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>19</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11851</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms231911851</ELocationID><Abstract><AbstractText>SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14,000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA-approved molecules with established safety profiles that have plausible mechanisms for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising drug candidates that can be repurposed for the safe, efficacious, and cost-effective treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx that was also developed to enable the scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>MacRaild</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-3694-3989</Identifier><AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Muzaffar-Ur-Rehman</ForeName><Initials>MU</Initials><Identifier Source="ORCID">0000-0002-5118-9005</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faheem</LastName><Identifier Source="ORCID">0000-0002-2306-3050</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, Rajasthan, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murugesan</LastName><ForeName>Sankaranarayanan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3680-1577</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Styles</LastName><ForeName>Ian K</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bio21 Institute, University of Melbourne, Parkville, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkpatrick</LastName><ForeName>Carl M J</ForeName><Initials>CMJ</Initials><AffiliationInfo><Affiliation>Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palombo</LastName><ForeName>Enzo A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0001-5889-1393</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Moana M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Hardik A</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0002-4129-3183</Identifier><AffiliationInfo><Affiliation>Department of Electrical and Electronics Engineering, Birla Institute of Technology and Science, Pilani 333031, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Vinti</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Information Systems, Birla Institute of Technology and Science, Pilani 333031, Rajasthan, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAuley</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-7632-9633</Identifier><AffiliationInfo><Affiliation>Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Portarlington Road, Geelong, VIC 3220, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anupama</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Commonwealth Scientific and Industrial Research Organisation, Land and Water, Waite Campus, SA 5064, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creek</LastName><ForeName>Darren J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0001-7497-7082</Identifier><AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevaskis</LastName><ForeName>Natalie L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0001-9538-549X</Identifier><AffiliationInfo><Affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasan</LastName><ForeName>Seshadri S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-7326-3210</Identifier><AffiliationInfo><Affiliation>Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Portarlington Road, Geelong, VIC 3220, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health, 189 Royal Street, East Perth, WA 6004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of York, York YO10 5DD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>75F40121C00144</GrantID><Agency>United States Food and Drug Administration</Agency><Country/></Grant><Grant><GrantID>MRF2009092</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">CoviRx.org</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Variants of Concern (VOC)</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">drugs</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">repurposing</Keyword><Keyword MajorTopicYN="N">therapies</Keyword><Keyword MajorTopicYN="N">treatments</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36233149</ArticleId><ArticleId IdType="pmc">PMC9569752</ArticleId><ArticleId IdType="doi">10.3390/ijms231911851</ArticleId><ArticleId IdType="pii">ijms231911851</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Director-General&#x2019;s Opening Remarks at the Media Briefing on COVID-19.  [(accessed on 2 February 2022)].  Available online:  https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.</Citation></Reference><Reference><Citation>Worldometer.  [(accessed on 2 February 2022)].  Available online:  https://www.worldometers.info/coronavirus/</Citation></Reference><Reference><Citation>The Pandemic&#x2019;s True Death Toll.  [(accessed on 29 September 2022)].  Available online:  https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates.</Citation></Reference><Reference><Citation>Avila J., Long B., Holladay D., Gottlieb M. Thrombotic Complications of COVID-19. Am. J. Emerg. Med. 2021;39:213&#x2013;218. doi: 10.1016/j.ajem.2020.09.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.09.065</ArticleId><ArticleId IdType="pmc">PMC7528743</ArticleId><ArticleId IdType="pubmed">33036855</ArticleId></ArticleIdList></Reference><Reference><Citation>Talasaz A.H., Kakavand H., van Tassell B., Aghakouchakzadeh M., Sadeghipour P., Dunn S., Geraiely B. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. Cardiovasc. Drugs Ther. 2021;35:249&#x2013;259. doi: 10.1007/s10557-020-07037-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07037-2</ArticleId><ArticleId IdType="pmc">PMC7360896</ArticleId><ArticleId IdType="pubmed">32671601</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins G.D., Ji C., Connolly B.A., Couper K., Lall R., Baillie J.K., Bradley J.M., Dark P., Dave C., de Soyza A., et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients with Acute Hypoxemic Respiratory Failure and COVID-19. JAMA. 2022;327:546. doi: 10.1001/jama.2022.0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0028</ArticleId><ArticleId IdType="pmc">PMC8787685</ArticleId><ArticleId IdType="pubmed">35072713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and Predictors of Long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilkington E.H., Suys E.J.A., Trevaskis N.L., Wheatley A.K., Zukancic D., Algarni A., Al-Wassiti H., Davis T.P., Pouton C.W., Kent S.J., et al. From Influenza to COVID-19: Lipid Nanoparticle MRNA Vaccines at the Frontiers of Infectious Diseases. Acta Biomater. 2021;131:16&#x2013;40. doi: 10.1016/j.actbio.2021.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2021.06.023</ArticleId><ArticleId IdType="pmc">PMC8272596</ArticleId><ArticleId IdType="pubmed">34153512</ArticleId></ArticleIdList></Reference><Reference><Citation>Eroglu B., Nuwarda R.F., Ramzan I., Kayser V. A Narrative Review of COVID-19 Vaccines. Vaccines. 2021;10:62. doi: 10.3390/vaccines10010062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010062</ArticleId><ArticleId IdType="pmc">PMC8779282</ArticleId><ArticleId IdType="pubmed">35062723</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Coronavirus Disease (COVID-19): Vaccines.  [(accessed on 30 September 2022)].  Available online:  https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines.</Citation></Reference><Reference><Citation>Zheng C., Shao W., Chen X., Zhang B., Wang G., Zhang W. Real-World Effectiveness of COVID-19 Vaccines: A Literature Review and Meta-Analysis. Int. J. Infect. Dis. 2022;114:252&#x2013;260. doi: 10.1016/j.ijid.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez D. Paxlovid: What We Know about Pfizer&#x2019;s COVID-19 Pill.  [(accessed on 30 September 2022)].  Available online:  https://www.pharmaceutical-technology.com/analysis/paxlovid-pfizer-covid-19-pill/</Citation></Reference><Reference><Citation>Merck  Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults with Mild-to-Moderate COVID-19.  [(accessed on 7 February 2022)].  Available online:  https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/</Citation></Reference><Reference><Citation>Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., Sheahan T.P., Baric R.S., Heise M.T., Swanstrom R. &#x3b2;-D-N4-Hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis but is Also Mutagenic to Mammalian Cells. J. Infect. Dis. 2021;224:415&#x2013;419. doi: 10.1093/infdis/jiab247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId><ArticleId IdType="pmc">PMC8136050</ArticleId><ArticleId IdType="pubmed">33961695</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH  The COVID-19 Treatment Guidelines Panel&#x2019;s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications.  [(accessed on 7 February 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/</Citation></Reference><Reference><Citation>NIH  Anti-SARS-CoV-2 Monoclonal Antibodies.  [(accessed on 7 February 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/</Citation></Reference><Reference><Citation>Tsirtsakis A. RACGP&#x2014;What is the Latest on COVID-19 Treatments Available in Australia?  [(accessed on 30 September 2022)].  Available online:  https://www1.racgp.org.au/newsgp/clinical/what-is-the-latest-on-covid-19-treatments-availabl.</Citation></Reference><Reference><Citation>Robinson B.W.S., Tai A., Springer K. Why We Still Need Drugs for COVID-19 and Can&#x2019;t Just Rely on Vaccines. Respirology. 2022;27:109&#x2013;111. doi: 10.1111/resp.14199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14199</ArticleId><ArticleId IdType="pmc">PMC9303302</ArticleId><ArticleId IdType="pubmed">34970812</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH  COVID-19 Treatment Guidelines: Corticosteroids.  [(accessed on 30 September 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/</Citation></Reference><Reference><Citation>Jain H.A., Agarwal V., Bansal C., Kumar A., Faheem F., Mohammed M.-U.-R., Murugesan S., Simpson M.M., Karpe A.V., Chandra R., et al.  CoviRx: A User-Friendly Interface for Systematic Down-Selection of Repurposed Drug Candidates for COVID-19. 2022.  [(accessed on 30 September 2022)].  Available online:  https://www.preprints.org/manuscript/202209.0323/v1.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson M., Poulsen S.-A. An Overview of Australia&#x2019;s Compound Management Facility: The Queensland Compound Library. ACS Chem. Biol. 2014;9:28&#x2013;33. doi: 10.1021/cb400912x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb400912x</ArticleId><ArticleId IdType="pubmed">24432754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.Z., Xu M., Pradhan M., Gorshkov K., Petersen J.D., Straus M.R., Zhu W., Shinn P., Guo H., Shen M., et al. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacol. Transl. Sci. 2020;3:1165&#x2013;1175. doi: 10.1021/acsptsci.0c00112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00112</ArticleId><ArticleId IdType="pmc">PMC7586456</ArticleId><ArticleId IdType="pubmed">33330839</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., Burgstaller-Muehlbacher S., de Jesus P.D., Teriete P., Hull M.V., et al. Discovery of SARS-CoV-2 Antiviral Drugs through Large-Scale Compound Repurposing. Nature. 2020;586:113&#x2013;119. doi: 10.1038/s41586-020-2577-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2577-1</ArticleId><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakowski M.A., Beutler N., Wolff K.C., Kirkpatrick M.G., Chen E., Nguyen T.-T.H., Riva L., Shaabani N., Parren M., Ricketts J., et al. Drug Repurposing Screens Identify Chemical Entities for the Development of COVID-19 Interventions. Nat. Commun. 2021;12:3309. doi: 10.1038/s41467-021-23328-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23328-0</ArticleId><ArticleId IdType="pmc">PMC8175350</ArticleId><ArticleId IdType="pubmed">34083527</ArticleId></ArticleIdList></Reference><Reference><Citation>Touret F., Gilles M., Barral K., Nougair&#xe8;de A., van Helden J., Decroly E., de Lamballerie X., Coutard B. In Vitro Screening of a FDA Approved Chemical Library Reveals Potential Inhibitors of SARS-CoV-2 Replication. Sci. Rep. 2020;10:13093. doi: 10.1038/s41598-020-70143-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70143-6</ArticleId><ArticleId IdType="pmc">PMC7403393</ArticleId><ArticleId IdType="pubmed">32753646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzikov M., Costanzi E., Reinshagen J., Esposito F., Vangeel L., Wolf M., Ellinger B., Claussen C., Geisslinger G., Corona A., et al. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. ACS Pharmacol. Transl. Sci. 2021;4:1096&#x2013;1110. doi: 10.1021/acsptsci.0c00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00216</ArticleId><ArticleId IdType="pmc">PMC7986981</ArticleId><ArticleId IdType="pubmed">35287429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinger B., Zaliani A., Claussen C., Reinshagen J., Kuzikov M., Wolf M., Gribbon P., Ciesek S. Identication of Inhibitors of SARS-CoV-2 in-Vitro Cellular Toxicity in Human (Caco-2) Cells Using a Large Scale Drug Repurposing Collection. 2020.  [(accessed on 30 September 2022)].  Available online:  https://www.researchsquare.com/article/rs-23951/v1.</Citation></Reference><Reference><Citation>Zaliani A., Vangeel L., Reinshagen J., Iaconis D., Kuzikov M., Keminer O., Wolf M., Ellinger B., Esposito F., Corona A., et al. Cytopathic SARS-CoV-2 Screening on VERO-E6 Cells in a Large-Scale Repurposing Effort. Sci. Data. 2022;9:405. doi: 10.1038/s41597-022-01532-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01532-x</ArticleId><ArticleId IdType="pmc">PMC9279437</ArticleId><ArticleId IdType="pubmed">35831315</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiser K., Mclean P.F., Davis C.T., Fogelson B., Gordon H.B., Jacobson P., Hurst B., Miller B., Alfa R.W., Earnshaw B.A., et al. Identification of Potential Treatments for COVID-19 through Artificial Intelligence-Enabled Phenomic Analysis of Human Cells Infected with SARS-CoV-2. bioRxiv. 2020 doi: 10.1101/2020.04.21.054387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.21.054387</ArticleId></ArticleIdList></Reference><Reference><Citation>Selleckchem.Com.  [(accessed on 7 February 2022)].  Available online:  https://www.selleckchem.com/</Citation></Reference><Reference><Citation>Microsource Discovery Systems.  [(accessed on 7 February 2022)].  Available online:  http://www.msdiscovery.com/spectrum.html.</Citation></Reference><Reference><Citation>PubChem.  [(accessed on 7 February 2022)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/</Citation></Reference><Reference><Citation>DrugBank.  [(accessed on 7 February 2022)].  Available online:  https://go.drugbank.com/</Citation></Reference><Reference><Citation>Drug Central 2021&#x2014;Online Drug Compendium&#x2014;Database Update.  [(accessed on 7 February 2022)].  Available online:  https://drugcentral.org/</Citation></Reference><Reference><Citation>ChEMBL.  [(accessed on 7 February 2022)].  Available online:  https://www.ebi.ac.uk/chembl/</Citation></Reference><Reference><Citation>ClinicalTrials.Gov  A Database of Privately and Publicly Funded Clinical Studies Conducted around the World.  [(accessed on 7 February 2022)]; Available online:  https://clinicaltrials.gov/</Citation></Reference><Reference><Citation>International Clinical Trials Registery Platform.  [(accessed on 7 February 2022)].  Available online:  https://trialsearch.who.int/Default.aspx.</Citation></Reference><Reference><Citation>Cule Repurposing.  [(accessed on 7 February 2022)].  Available online:  https://clue.io/repurposing-app.</Citation></Reference><Reference><Citation>Binding DB  The Binding Database.  [(accessed on 7 February 2022)].  Available online:  https://www.bindingdb.org/bind/index.jsp.</Citation></Reference><Reference><Citation>Drugs@FDA: FDA&#x2014;Approved Drugs.  [(accessed on 7 February 2022)]; Available online:  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.</Citation></Reference><Reference><Citation>ARTG Search.  [(accessed on 7 February 2022)].  Available online:  https://tga-search.clients.funnelback.com/s/search.html?query=&amp;collection=tga-artg.</Citation></Reference><Reference><Citation>Prescribing Medicines in Pregnancy Database.  [(accessed on 7 February 2022)]; Available online:  https://www.tga.gov.au/prescribing-medicines-pregnancy-database.</Citation></Reference><Reference><Citation>(LactMed)&#x2014;National Library of Medicine (US)  Drugs and Lactation Database.  [(accessed on 7 February 2022)]; Available online:  https://www.ncbi.nlm.nih.gov/books/NBK501922/</Citation></Reference><Reference><Citation>Medscape.  [(accessed on 7 February 2022)].  Available online:  https://reference.medscape.com/</Citation></Reference><Reference><Citation>KEGG Database.  [(accessed on 7 February 2022)].  Available online:  https://www.kegg.jp/kegg/</Citation></Reference><Reference><Citation>ATC Index.  [(accessed on 7 February 2022)].  Available online:  https://www.whocc.no/atc_ddd_index/</Citation></Reference><Reference><Citation>WHO Solidarity Trial Consortium Repurposed Antiviral Drugs for COVID-19&#x2014;Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.A. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. Front. Immunol. 2021;12:653. doi: 10.3389/fimmu.2021.635371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.635371</ArticleId><ArticleId IdType="pmc">PMC7990901</ArticleId><ArticleId IdType="pubmed">33777024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., et al. Drug Repurposing: Progress, Challenges and Recommendations. Nat. Rev. Drug Discov. 2019;18:41&#x2013;58. doi: 10.1038/nrd.2018.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker E.H., Gnjidic D., Kirkpatrick C.M.J., Pirmohamed M., Wright D.F.B., Zecharia A.Y. A Call for the Appropriate Application of Clinical Pharmacological Principles in the Search for Safe and Efficacious COVID-19 (SARS-CoV-2) Treatments. Br. J. Clin. Pharmacol. 2021;87:707&#x2013;711. doi: 10.1111/bcp.14416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14416</ArticleId><ArticleId IdType="pubmed">32515023</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummino T.A., Rezelj V.V., Fischer B., Fischer A., O&#x2019;Meara M.J., Monel B., Vallet T., White K.M., Zhang Z., Alon A., et al. Drug-Induced Phospholipidosis Confounds Drug Repurposing for SARS-CoV-2. Science. 2021;373:541&#x2013;547. doi: 10.1126/science.abi4708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4708</ArticleId><ArticleId IdType="pmc">PMC8501941</ArticleId><ArticleId IdType="pubmed">34326236</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlin J.L., Auld D.S., Rothenaigner I., Haney S., Sexton J.Z., Nissink J.W.M., Walsh J., Lee J.A., Strelow J.M., Willard F.S., et al. Nuisance Compounds in Cellular Assays. Cell Chem. Biol. 2021;28:356&#x2013;370. doi: 10.1016/j.chembiol.2021.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2021.01.021</ArticleId><ArticleId IdType="pmc">PMC7979533</ArticleId><ArticleId IdType="pubmed">33592188</ArticleId></ArticleIdList></Reference><Reference><Citation>Baell J.B., Holloway G.A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem. 2010;53:2719&#x2013;2740. doi: 10.1021/jm901137j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm901137j</ArticleId><ArticleId IdType="pubmed">20131845</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Why You Should Not Use Ivermectin to Treat or Prevent COVID-19.  [(accessed on 7 February 2022)]; Available online:  https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19.</Citation></Reference><Reference><Citation>Matt Woodley TGA Issues Fresh Warning over Ivermectin as COVID Treatment.  [(accessed on 7 February 2022)].  Available online:  https://www1.racgp.org.au/newsgp/clinical/tga-issues-warning-over-ivermectin-as-covid-treatm.</Citation></Reference><Reference><Citation>Bray M., Rayner C., No&#xeb;l F., Jans D., Wagstaff K. Ivermectin and COVID-19: A Report in Antiviral Research, Widespread Interest, an FDA Warning, Two Letters to the Editor and the Authors&#x2019; Responses. Antivir. Res. 2020;178:104805. doi: 10.1016/j.antiviral.2020.104805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104805</ArticleId><ArticleId IdType="pmc">PMC7172803</ArticleId><ArticleId IdType="pubmed">32330482</ArticleId></ArticleIdList></Reference><Reference><Citation>Popp M., Stegemann M., Metzendorf M.-I., Gould S., Kranke P., Meybohm P., Skoetz N., Weibel S. Ivermectin for Preventing and Treating COVID-19. Cochrane Database Syst. Rev. 2021;2021:CD015017. doi: 10.1002/14651858.CD015017.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD015017.pub2</ArticleId><ArticleId IdType="pmc">PMC8406455</ArticleId><ArticleId IdType="pubmed">34318930</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulakurthi Y.S., Pederson J.M., Saravu K., Gupta N., Balasubramanian P., Kamrowski S., Schmidt M., Vegivinti C.T.R., Dibas M., Reierson N.L., et al. Corticosteroid Therapy for COVID-19. Medicine. 2021;100:e25719. doi: 10.1097/MD.0000000000025719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000025719</ArticleId><ArticleId IdType="pmc">PMC8137023</ArticleId><ArticleId IdType="pubmed">34011029</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH  Table: Systemic Corticosteroids Clinical Data|COVID-19 Treatment Guidelines.  [(accessed on 30 September 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/tables/systemic-corticosteroids-data/</Citation></Reference><Reference><Citation>Dayer M.R. Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective. arXiv. 20202003.04524</Citation></Reference><Reference><Citation>Alonzi T., Aiello A., Petrone L., Najafi Fard S., D&#x2019;Eletto M., Falasca L., Nardacci R., Rossin F., Delogu G., Castilletti C., et al. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. Cells. 2021;11:52. doi: 10.3390/cells11010052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11010052</ArticleId><ArticleId IdType="pmc">PMC8750154</ArticleId><ArticleId IdType="pubmed">35011614</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoene J., Gavin R.F., Towne A., Wattay L., Ferrari M.G., Pal R. In Vitro Activity of Cysteamine Against SARS-CoV-2 Variants. bioRxiv. 2022 doi: 10.1016/j.ymgme.2022.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2022.08.009</ArticleId><ArticleId IdType="pmc">PMC9444157</ArticleId><ArticleId IdType="pubmed">36115282</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley A.J., van Vuren P.J., Mohammed M.-U.-R., Faheem F., Goldie S., Riddell S., G&#xf6;dde N.J., Styles I.K., Bruce M.P., Chahal S., et al.  Use of Human Lung Tissue Models for Screening of Drugs Against SARS-CoV-2 Infection. 2022.  [(accessed on 30 September 2022)].  Available online:  https://www.preprints.org/manuscript/202209.0288/v1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9693925</ArticleId><ArticleId IdType="pubmed">36366514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischof E., Siow R.C., Zhavoronkov A., Kaeberlein M. The Potential of Rapalogs to Enhance Resilience against SARS-CoV-2 Infection and Reduce the Severity of COVID-19. Lancet Healthy Longev. 2021;2:e105&#x2013;e111. doi: 10.1016/S2666-7568(20)30068-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(20)30068-4</ArticleId><ArticleId IdType="pmc">PMC7906698</ArticleId><ArticleId IdType="pubmed">33665645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Hou Y., Shen J., Huang Y., Martin W., Cheng F. Network-Based Drug Repurposing for Novel Coronavirus 2019-NCoV/SARS-CoV-2. Cell Discov. 2020;6:14. doi: 10.1038/s41421-020-0153-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0153-3</ArticleId><ArticleId IdType="pmc">PMC7073332</ArticleId><ArticleId IdType="pubmed">32194980</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmenero J., Rodr&#xed;guez-Per&#xe1;lvarez M., Salcedo M., Arias-Milla A., Mu&#xf1;oz-Serrano A., Graus J., Nu&#xf1;o J., Gastaca M., Bustamante-Schneider J., Cachero A., et al. Epidemiological Pattern, Incidence, and Outcomes of COVID-19 in Liver Transplant Patients. J. Hepatol. 2021;74:148&#x2013;155. doi: 10.1016/j.jhep.2020.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.07.040</ArticleId><ArticleId IdType="pmc">PMC7395653</ArticleId><ArticleId IdType="pubmed">32750442</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrazzano G., Rubino V., Palatucci A.T., Giovazzino A., Carriero F., Ruggiero G. An Open Question: Is It Rational to Inhibit the MTor-Dependent Pathway as COVID-19 Therapy? Front. Pharmacol. 2020;11:856. doi: 10.3389/fphar.2020.00856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00856</ArticleId><ArticleId IdType="pmc">PMC7273850</ArticleId><ArticleId IdType="pubmed">32574238</ArticleId></ArticleIdList></Reference><Reference><Citation>Heron V.C., Bach C.-A.T., Holmes N.E., Whitlam J.B. Complete Recovery from COVID-19 of a Kidney-Pancreas Transplant Recipient: Potential Benefit from Everolimus? BMJ Case Rep. 2021;14:e238413. doi: 10.1136/bcr-2020-238413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-238413</ArticleId><ArticleId IdType="pmc">PMC7802699</ArticleId><ArticleId IdType="pubmed">33431539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R., Lavezzi A.M. Neuropathological Explanation of Minimal COVID-19 Infection Rate in Newborns, Infants and Children&#x2014;A Mystery so Far. New Insight into the Role of Substance P. J. Neurol. Sci. 2021;420:117276. doi: 10.1016/j.jns.2020.117276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117276</ArticleId><ArticleId IdType="pmc">PMC7834711</ArticleId><ArticleId IdType="pubmed">33360484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R. Neurokinin-1 Receptor as a Potential Drug Target for COVID-19 Treatment. Biomed. Pharmacother. 2021;143:112159. doi: 10.1016/j.biopha.2021.112159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112159</ArticleId><ArticleId IdType="pmc">PMC8435369</ArticleId><ArticleId IdType="pubmed">34536760</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R., Kurdi M., Bamaga A., Aldardeir N., Nasief H., Moshref L.H., Alsinani T., Rayes A.O., Jabbad R.H. Substance P/Neurokinin-1 Receptor, Trigeminal Ganglion, Latency, and Coronavirus Infection-Is There Any Link? Front. Med. 2021;8:727593. doi: 10.3389/fmed.2021.727593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.727593</ArticleId><ArticleId IdType="pmc">PMC8637107</ArticleId><ArticleId IdType="pubmed">34869423</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinoso-Arija R., L&#xf3;pez-Ram&#xed;rez C., Jimenez-Ruiz J.A., L&#xf3;pez-Campos J.L. Effectiveness of Aprepitant in Post-acute COVID-19 Syndrome. Clin. Case Rep. 2021;9:e04646. doi: 10.1002/ccr3.4646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.4646</ArticleId><ArticleId IdType="pmc">PMC8449093</ArticleId><ArticleId IdType="pubmed">34567551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodds M., Xiong Y., Mouksassi S., Kirkpatrick C.M., Hui K., Doyle E., Patel K., Cox E., Wesche D., Brown F., et al. Model-informed Drug Repurposing: A Pharmacometric Approach to Novel Pathogen Preparedness, Response and Retrospection. Br. J. Clin. Pharmacol. 2021;87:3388&#x2013;3397. doi: 10.1111/bcp.14760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14760</ArticleId><ArticleId IdType="pmc">PMC8013376</ArticleId><ArticleId IdType="pubmed">33534138</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Pharmacology Resource Centre  In Silico Workbench.  [(accessed on 7 February 2022)].  Available online:  https://www.covidpharmacology.com/in-silico-workbench/</Citation></Reference><Reference><Citation>RDKit  Open-Source Cheminformatics.  [(accessed on 7 February 2022)].  Available online:  https://www.rdkit.org/</Citation></Reference><Reference><Citation>Jasial S., Hu Y., Bajorath J. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. J. Med. Chem. 2017;60:3879&#x2013;3886. doi: 10.1021/acs.jmedchem.7b00154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b00154</ArticleId><ArticleId IdType="pubmed">28421750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter F.M.I., Bento A.P., Bosc N., Gaulton A., Hersey A., Leach A.R. Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs. Chem. Res. Toxicol. 2021;34:385&#x2013;395. doi: 10.1021/acs.chemrestox.0c00296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.0c00296</ArticleId><ArticleId IdType="pmc">PMC7888266</ArticleId><ArticleId IdType="pubmed">33507738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C., Mangalaganesh S., Wilson L.O.W., Kuiper M.J., Drew T.W., Vasan S.S. Tracking Co-Occurrence of N501Y, P681R, and Other Key Mutations in SARS-CoV-2 Spike for Surveillance. Zoonotic Dis. 2022;2:147&#x2013;162. doi: 10.3390/zoonoticdis2030014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/zoonoticdis2030014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>